Company intelligence / Profile preview

Antisoma

Ownership: Private
Development stage: Phase 3

Overview

Antisoma developed several oncology drug candidates. Its lead asset ASA404 entered Phase III trials for cancer treatment in partnership with Novartis. Another key program was Xanafide for secondary AML in Phase III. Oral fludarabine was submitted to the FDA for CLL. The company had additional preclinical programs targeting Flt3 and other pathways. Despite promising early results and major partnerships/funding milestones—such as a $75M upfront deal with Novartis—none of the lead assets reached commercialization before the company's closure or absorption by others

Therapeutic areas: Oncology
Modalities: Small moleculesVascular disrupting agents (VDAs)DNA-intercalating agents
Industry: Biotech

Drug pipeline

2 assets

vadimezan

Phase 3

Indications: Cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Novartis – major licensing/development deal for ASA404 including significant milestone payments and royalties

Beyond the preview

Go deeper on Antisoma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antisoma.

Explore the full profile